No Single Right Box: What a Landmark Trial of 316 Children Reveals About Treating Anxiety

A Singular Point of View

If you are holding a referral letter for your child right now, wondering whether to tick the box for talking therapy or the box for medication, this one is for you.

Picture two doors at the end of a corridor, both closed, both unmarked, and you standing in front of them with a form in your hand and a pen that suddenly feels heavier than it should. One door says “medication.” The other says “talking therapy.” Nobody has told you what waits behind either one, only that you must choose, and choose soon, because the appointment is next Tuesday and the school has already asked twice. Perhaps you are still waiting for the assessment that will make this official. Perhaps the diagnosis came through only last week. Perhaps the letter arrived from school, not from a clinic, and you are working out, right now, what happens next. Wherever you are in that corridor, a large new trial has just switched the lights on — and what it shows is not what most parents expect.

The trial that finally asked the real question

Anxiety in children is not rare, and you may already know that in your own house — at half past eleven on a bad night when the worries will not stop, in the mornings that start with a stomach ache that is not really a stomach ache, in the school run that takes twenty minutes longer than it should. Researchers at Children’s Hospital Los Angeles (CHLA), who led this study, put the figure at around one in five young people having a diagnosable anxiety disorder by the age of eighteen. Bradley Peterson, the psychiatrist who co-led the trial, calls it plainly: “We are in an epidemic of anxiety.”

What has been missing, until now, is solid evidence about which treatment to reach for first. You have probably been offered one of two things: cognitive behavioural therapy (CBT — a structured talking therapy that helps someone notice and gradually change anxious thinking and avoidance patterns), or an antidepressant such as fluoxetine. Clinical guidelines have generally nudged families towards trying CBT first. But that guidance rested on trials that mostly studied children from comfortable, stable backgrounds with few other difficulties layered on top — and your family, like most, probably does not look like that.

So Peterson, together with clinical psychologist Amy West, designed something more honest: a real-world trial, funded by the Patient-Centered Outcomes Research Institute (PCORI), enrolling 316 young people aged 8 to 17 from across Los Angeles County — children from every socioeconomic level and racial and ethnic group, many of them also managing depression, school difficulties or substance use alongside their anxiety. It was not a trial built to flatter one treatment. It was built to find out what actually happens when anxiety turns up in a life that is already complicated — the kind of life your child is probably living.

Does your child fit neatly into a textbook case? Probably not. Almost no one’s does. That is exactly who this trial was designed for, and exactly who most previous research left out.

What the 24 weeks showed

Every participant was randomly assigned, for the first twelve weeks, to either fluoxetine or CBT. At the twelve-week mark, each young person either continued their original treatment or added the other one on top. Anxiety was tracked throughout using the SCARED scale, a standard screening questionnaire completed by young people themselves, and across the full 24 weeks, scores fell by an average of 31.7 per cent.

Here is the finding that matters most for the form in your hand: there was no clearly superior single approach. CBT held a slight edge over starting with medication, but the difference was not statistically significant. Non-Hispanic white participants tended to do somewhat better staying on fluoxetine throughout; participants from minority backgrounds tended to do somewhat better when a combination was added partway through. For those who began with CBT, adding fluoxetine after twelve weeks improved their odds further.

“The good news is that, in general, the treatments appear to be similarly effective in reducing anxiety, so treatment choice can depend on family preference, accessibility, and other individual or contextual factors,” Dr West has said of the results. Peterson goes further, suggesting the finding could reshape guidelines that have long favoured CBT as the default first step: “It’s perfectly reasonable to begin with medication if that’s what is accessible and is what works for the patient.”

It was not one clear winner. It was several honest, workable doors. And you have permission to choose whichever one you can actually walk through.

Where this touches ADHD

This trial was not built around ADHD (attention-deficit/hyperactivity disorder), and that is worth saying plainly rather than stretching the finding further than the data allow: this next part goes beyond what the researchers themselves tested. But anxiety and ADHD travel together far more often than either does alone — somewhere around one in three children with ADHD also meets criteria for an anxiety disorder, and the overlap can make each condition harder to spot underneath the other. If your child cannot settle to homework, is it the ADHD, the anxiety, or both? Very often it is both at once. If your son or daughter already has an ADHD diagnosis and anxiety has crept in alongside it, this trial’s central message still holds for you: the treatment that works is very often the one your family can actually access and sustain, not the one that ranks marginally higher on a research chart.

What this cannot promise you

Before you take this to your GP or your child’s paediatrician, it is worth knowing what this study cannot promise you — not to unsettle you, but to protect you from a false certainty that could let you down later. It followed young people for six months, with a year of further follow-up now published and six more years of funded tracking still to come, so nobody yet knows whether these gains hold as your child grows older. It compared fluoxetine specifically, not every medication used for paediatric anxiety, and it measured CBT’s effectiveness in real clinics with real variation in how well any individual therapist delivers it; Dr West herself notes that the quality of CBT delivery is something the team wants to study far more closely. The differences seen between ethnic groups, while genuinely observed, come from a single trial and will need repeating before you or anyone else treats them as settled fact.

Let me slow down here, because hope without honesty helps no one. “Similarly effective on average” is not the same as “certain to work for your child.” Averages describe crowds. Your child is not a crowd.

What you can do this week

Start with what is genuinely available near you. Waiting lists for CBT vary enormously; this trial’s finding that starting with medication is a reasonable, evidence-backed choice means you are not settling for second-best if therapy access is the bottleneck where you live. Then ask what your child can actually sustain, because a treatment only works if someone keeps showing up to it — weekly sessions for a child who dreads car journeys, or a daily tablet for a child who struggles to swallow pills, are both real practical obstacles worth naming out loud to your clinician, not private failures to hide from them.

Give whichever door you choose a proper twelve weeks before deciding it has failed; that was the trial’s own rhythm, and it is a useful one to borrow even outside a research study. If progress stalls at that point, ask about adding rather than switching — the data suggest that layering a second approach on top of the first, rather than abandoning it and starting over, was often more helpful. And if attention or executive function difficulties (the mental skills involved in planning, starting tasks and regulating focus) are already part of the picture, say so, out loud, to whoever is treating the anxiety. The two conditions can mask and amplify one another, and treatment works better when the person treating your child can see the whole of them.

The door you can reach

You do not need to find the perfect door to open. The researchers who ran this trial, working with real families in real circumstances, could not find one either — and they looked harder than almost anyone has looked before. What they found instead was something more useful than a single right answer: several treatments that genuinely help, and permission to choose based on what fits your family rather than what tops a league table nobody ever showed you. Tick the box for the door you can actually walk your child through, week after week. That, the evidence now says, is very likely to be the right one.

---

Source: Peterson, B.S., West, A.E., et al., “A Pragmatic SMART Study of Medication and CBT Sequencing in Pediatric Anxiety Disorders: A Randomized Clinical Trial,” American Journal of Psychiatry, 2026 (DOI 10.1176/appi.ajp.20251037); Children’s Hospital Los Angeles press release, 24 June 2026; HealthDay, 8 July 2026.